Loading clinical trials...
Loading clinical trials...
A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Trial to Evaluate the Efficacy, Safety, and Tolerability of Tralokinumab Monotherapy in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) Who Are Candidates for Systemic Therapy
Conditions
Interventions
Tralokinumab
Placebos
Locations
87
United States
LEO Pharma Investigational Site
Birmingham, Alabama, United States
LEO Pharma Investigational Site
Fort Smith, Arkansas, United States
Leo Pharma Investigational Site
Fountain Valley, California, United States
LEO Pharma Investigational Site
Los Angeles, California, United States
LEO Pharma Investigational Site
San Francisco, California, United States
LEO Pharma Investigational Site
Stanford, California, United States
Start Date
June 19, 2018
Primary Completion Date
April 15, 2020
Completion Date
March 16, 2021
Last Updated
March 11, 2025
NCT07217015
NCT07298395
NCT06116526
NCT06461897
NCT07262983
NCT06389136
Lead Sponsor
LEO Pharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions